Department of Acupuncture, Guang'an Men Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
World J Urol. 2020 Apr;38(4):1035-1042. doi: 10.1007/s00345-019-02828-1. Epub 2019 Jun 3.
To compare the effects and safety of electroacupuncture (EA) and the integration of pelvic floor muscle training (PFMT) and solifenacin in women with urgency-predominant mixed urinary incontinence (MUI).
The study was a secondary analysis of a randomized noninferiority trial which recruited 500 women with MUI and randomized 178 with urgency-predominant MUI to either receive 12-week EA treatment and 24-week follow-up or 36-week PFMT-solifenacin treatment. Clinical response was defined as at least 50% reduction in average 24-h urgency incontinence episode frequency (IEF), measured by 72-h voiding diary through weeks 1-12.
Of the patients randomized, 173 completed the study. The clinical response was 45.78% in EA group, similar with 50.0% in PFMT-solifenacin group, with a difference of - 3.54 (95% CI - 19.08 to 12.0; P = 0.66). In both groups, the proportion of patients with at least 50% reduction of IEF and stress IEF were improved, while the score of ICIQ-SF, episodes of urination, nocturia and urgency, 1-h amount of urinary leakage (AUL), proportion of patients using pads and the number consumed were all decreased after 12-week treatment. The effects could sustain till 36 weeks. Adverse events occurred less in EA group.
EA might reduce IEF, AUL and improve the life quality of female patients with urgency-predominant MUI. The effect may sustain till 36 weeks.
比较电针（EA）与盆底肌训练（PFMT）联合索利那新治疗以急迫症状为主的混合性尿失禁（MUI）女性的疗效和安全性。
本研究为一项随机非劣效性试验的二次分析，共纳入 500 例以急迫症状为主的 MUI 女性，其中 178 例随机分为 EA 治疗 12 周和 24 周随访组或 PFMT-索利那新治疗 36 周组。临床缓解定义为通过 72 小时排尿日记在第 1-12 周内平均 24 小时急迫性尿失禁发作频率（IEF）至少减少 50%。
随机分组的患者中，173 例完成研究。EA 组临床缓解率为 45.78%，与 PFMT-索利那新组的 50.0%相似，差异为-3.54（95%CI-19.08 至 12.0；P=0.66）。两组患者 IEF 和压力性 IEF 至少减少 50%的比例均增加，而 ICIQ-SF 评分、排尿次数、夜尿症和急迫性、1 小时尿失禁量（AUL）、使用尿垫的患者比例和消耗量均减少，12 周治疗后均改善，疗效可维持至 36 周。EA 组不良反应较少。
EA 可能减少以急迫症状为主的 MUI 女性的 IEF、AUL，改善其生活质量，疗效可持续至 36 周。
